Elios' dendritic cell vaccine leads to no significant difference in recurrence in Phase IIb for melanoma

Elios Therapeutics LLC (Austin, Texas) reported interim data from 120 patients with stage III or IV resected melanoma in a Phase IIb trial showing that the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine led to no significant difference in recurrence rate in the intent-to-treat (ITT) population vs. placebo at a median follow-up of 11.9 months (56.6% vs. 54.1%, p=0.65). In the per treatment population, which excluded early recurrences during the primary vaccine series, TLPLDC led to a recurrence rate of 29.4% vs. 43.3% for placebo at a median follow-up of 12.6 months (p=0.07). TLPLDC was well tolerated with no serious adverse events reported. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago...